Centocor, Inc.

Janssen Biotech, Inc.

Centecor, Inc.

Centocor Ortho Biotech Inc.

Other

Ethicon, Gmbh

University of Oklahoma

Cna Development LLC

George A Heavner

David M Knight

Bernard Scallon

Jill M Giles-Komar

David J Shealy

Marian Kruszynski

Jinquan Luo

David Peritt

Miljenko Mervic

John Ghrayeb

Thomas C Nesspor

Leon A Epps

Rodger P McEver

Chichi Huang

Douglas James Riexinger

Jian-Guo Geng

Anna Gosiewska

Raymond W Sweet

Karyn O'Neil

Sridevi N Dhanaraj

Linda Snyder

Jing Yang

Chin-Feng Yi

Mohit Trikha

Robert W Weber

Robert E Jordan

Ray Sweet

Karen A Kutoloski

Ali Rezania

Xuanhan Lin

Margaret L Falcone

Karyn O'neil

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Method of treating lupus by administering an anti-IL-12 antibody

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

Anti-TNF antibodies, compositions, methods and uses

Nucleic acids encoding anti-IL-12 antibody

Method of treating Crohn's disease by administering an anti-IL-12 antibody

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis.

Method for treating psoriatic arthritis by administering an anti-IL-12 antibody

The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing.

Fusion proteins of alpha-MSH derivatives and Fc

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.

Method for treating psoriasis by administering an anti-IL-12 antibody

Anti-IL-12 antibodies

The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.

The invention relates to a method of directing selection of biological therapeutic molecules to specific functional domains of the target biologic molecule. Selection is directed by the use of closely related molecules, where one is a decoy and the other contains the targeted domain or epitope. The invention is based on the use of physical data, which may be combined with derived data, to ascertain that the decoy and the target differ only in the specific functional domain or epitope where the binding will be directed.

Solution phase biopanning method using engineered decoy proteins

The present invention relates to at least one human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Human EPO mimetic hinge core mimetibodies, compositions, methods and uses

Growing community of inventors

Malvern, PA, United States of America

George A Heavner